Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 18, 2017HaematologicaOpen Access

Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDelphine RéaInstitut BergoniéGHGuylaine HenryBiparZKZena KhaznadarInserm

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Réa et al. (2017) studied this question.

synapsesocial.com/papers/6a12efcc13ab6312a8c0bef1https://doi.org/10.3324/haematol.2017.165001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education2010 · 743 citations
  2. 2Natural-killer cells and dendritic cells: “l'union fait la force”2005 · 637 citations
  3. 3Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?2014 · 138 citations
  4. 4Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia2016 · 504 citations
  5. 5The concept of treatment-free remission in chronic myeloid leukemia2016 · 253 citations